Journal article icon

Journal article

Will booster doses be required for serogroup B meningococcal vaccine?

Abstract:

The European licensure of 4CMenB, the first vaccine licensed to prevent non-epidemic meningococcal B (MenB) disease, marked an important milestone in the fight against meningococcal disease. However, the potential introduction of 4CMenB into the routine infant schedule is complicated by a number of factors. The recent decline in the number of cases of invasive MenB disease in the UK has important implications for cost effectiveness, though the unpredictable nature of meningococcal disease epi...

Expand abstract

Actions


Access Document


Authors


McQuaid, F More by this author
Journal:
Expert review of vaccines
Volume:
13
Issue:
3
Pages:
313-315
Publication date:
2014-03-05
DOI:
EISSN:
1744-8395
ISSN:
1476-0584
URN:
uuid:7f2b6dcd-cfe4-4437-8dfd-deab56c7d66d
Source identifiers:
452044
Local pid:
pubs:452044

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP